| abstract |
Anthranilic acid amides, which comprise a compound of the formula (1), wherein: R1 is a residue of formulas (2), (3), (4) or (5); A is -CnH2n-; n is 0, 1, 2, 3, 4 or 5; O is oxygen; D is a bond or oxygen; E is -CmH2m-; m is 0, 1, 2, 3, 4 or 5; R8 is hydrogen, C1-4 alkyl or CpH2p-R14; p is 0, 1, 2, 3, 4 or 5; R14 is C3-6 cycloalkyl, aryl or heteroaryl, aryl and heteroaryl being unsubstituted or being substituted with 1, 2 or 3 substituents chosen from the group consisting of F, Cl, Br, I, CF3, OCF3, NO2, CN, COOMe, CONH2, COMe, NH2, OH, C1-4 alkyl, C1-4 alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R9 is hydrogen or C1-6 alkyl; R 10 is hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, aryl or heteroaryl, aryl and heteroaryl being unsubstituted or being substituted as defined above; R 11 is C 3-6 cycloalkyl, phenyl, naphthyl, thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl or pyrimidyl, with phenyl, naphthyl, thienyl, furyl, pyridyl, pyrazinyl, pyridazinyl and pyrimidyl unsubstituted or substituted with 1, 2 or 3 substituents chosen from the group consisting of F, Cl, Br, I, CF3, OCF3, NO2, CN, COMe, NH2, OH, C1-4 alkyl, C1-4 alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R 12 is C 1-4 alkyl, C 3-6 cycloalkyl, aryl or heteroaryl, aryl and heteroaryl being unsubstituted or being substituted as defined above; R13 is CpH2p-R14; p is 0, 1, 2, 3, 4 or 5: R14 is C3-6 cycloalkyl, tetrahydrofuranyl, tetrahydropyranyl, aryl or heteroaryl, aryl and heteroaryl being unsubstituted or being substituted as defined above; R15 is C3-8 cycloalkyl; R2 is hydrogen or C1-4 alkyl; R3 is C3-7 alkyl, C3-6 cycloalkyl, phenyl or naphthyl, with phenyl or naphthyl being unsubstituted or being substituted with 1, 2 or 3 substituents chosen from the group consisting of F, Cl, Br, I, CF3, OCF3, NO2 , CN, COOMe, CONH2, COMe, NH2, OH, C1-4 alkyl, C1-4 alkoxy, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; R4, R5, R6 and R7, independently of each other, are hydrogen, F, Cl, Br, I, CF3, OCF3, OCHF2, NO2, CN, COOMe, CONH2, COMe, NH2, OH, C1-4 alkyl, alkoxy C1-4, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; and its pharmaceutically acceptable salts, which act on the potassium channel Kv1.5 and inhibit in the human atrium a potassium current called "delayed rectifier of ultra-rapid activation". Therefore, the compounds are very particularly suitable as new antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (atrial fibrillation, AF) or atrial trembling (atrial formulation); pharmaceutical compositions and the use of said amides for the manufacture of a medicament. |